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In the past couple of years, there has been a growing focus on the need to make scientific output accessible to a
greater number of people, especially in the field of clinical research. The public are being urged to become more
well-informed and to ask their doctors about taking part in clinical trials.
A key finding of a report from the Association of Medical Research Charities was that all published scientific papers
would benefit from having a section in plain English. Researchers running a clinical trial are expected to provide a
summary of their intended research at various stages of the research process. However, there is evidence that
existing summaries are of variable length and quality and not always in plain English.
As a result, the National Institute for Health Research (NIHR) commissioned a review of the guidance that is
available to researchers. However, recent initiatives demonstrate that there are still a number of challenges in
making current research both accessible and understandable by prospective participants.
BioMed Central also has a number of ongoing initiatives involving trial registration services and journals.
Keywords: Trial, Transparency, Plain english, Lay summary, GuidanceBackground
In the past couple of years, there has been a growing
focus on the need to make scientific output accessible to
a greater number of people, especially in the field of
clinical research.
Under the NHS Constitution, patients have the right
to be informed about relevant and appropriate clinical
research [1]. The public are being urged to become more
well-informed and to ask their doctors about taking part
in clinical trials. The debate about access to research
results has led to a House of Commons Select Committee
inquiry [2]. This short article looks at a number of recent
initiatives in the UK and explains how open-access
publisher BioMed Central is approaching the task.
In 2011, the National Institute for Health Research
(NIHR) launched a website listing all clinical trials that
have recruited or are actively recruiting participants in
the UK, the UK Clinical Trials Gateway website [3]. The
information on this website comes from two publicly
available sources of information, ClinicalTrials.gov [4] and* Correspondence: helene.faure@controlled-trials.com
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distribution, and reproduction in any mediumthe International Standard Randomised Controlled Trial
Number Register (ISRCTN) [5], which were primarily
set up to ensure that researchers were open about their
research and to allow health professionals reviewing
clinical evidence to bridge the gap between published
and unpublished research. The registers have since
evolved to become a point of reference for patients and
the general public.Summaries in plain English
Also in 2011, the Association of Medical Research Charities
[6], in collaboration with the British Library and the United
Kingdom Office for Library and Information Networking
(UKOLN) at the University of Bath, started the Patients
Participate! initiative, which examined how patients and
the general public could be given the right tools to make
sense of the increasing number of research outcomes as
reported in the press and media. One of the key findings of
their report was that all published scientific papers would
benefit from having a section in plain English, which is
currently far from being the case.
Researchers running a clinical trial are expected to
provide a summary of their intended research at various
stages of the research process (funding grant application,entral Ltd. This is an Open Access article distributed under the terms of the
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requirements are likely to differ from one stage to the
next. In 2013, there is evidence that existing summaries
will be of variable length and quality and not always in
plain English. The UK Clinical Trials Gateway may meet
its objective of providing a one-stop environment for trials
recruiting in the UK but, by reusing the content found
under the ‘lay summary’ or ‘research summary’ sections,
as required by a number of research funders, it is highly
unlikely to meet its objective of providing patients and the
public with information in an accessible and clear format.
Conversely, if the UK Clinical Trials Gateway really does
aim to maximize participation in clinical research, this will
raise the bar in terms of lay-friendliness of the information
that is presented.Guidance for researchers
As a result, the National Institute for Health Research
(NIHR) commissioned a review of the guidance that is
available to its own researchers. INVOLVE, the NIHR-
funded body that promotes the involvement of the public,
consulted a number of stakeholders and in January 2013
produced a report [7] stressing the needs:
 To explain to researchers why summaries in plain
(rather than scientific) English are important.
 To give advice on how to write in plain English [8].
 To aim for content that uses English at the same
level as would be found in a broadsheet newspaper.
Ensuring that future plain English summaries meet
quality standards could become a requirement for NIHR
funding, although the detail of implementation has yet
to be determined.Journal involvement
The NIHR is also building on the reputation of the
highly regarded journal Health Technology Assessment
[9] and will very soon be launching its own library of
journals [10]. This will ensure that all NIHR-funded
research can be disseminated in a timely and permanently
accessible manner. This implementation will rely on the
input of both health professionals and members of the
public.
As a publisher of over 160 journals in the field of medi-
cine, BioMed Central is actively involved in improving
clinical trial transparency via its open-access model [11].
BioMed Central administers the ISRCTN register. This is
very much seen as the first step towards transparency and
future dissemination of research outcomes. Each ISRCTN
record has a dedicated field that can be used by researchers
to describe their work in plain English, following guidelines
adopted from the CancerHelp UK model [12].Perceived difficulties
Some journals within the BioMed Central portfolio already
offer the option of providing a lay abstract with a research
paper. There is a small but growing demand for lay
summaries but the quality of lay summaries provided var-
ies. To write a good summary requires a specific skill set.
Researchers who are sometimes too close to their topic
might not be the best people to write these summaries.
Journal editors may also find it challenging to provide
such summaries for peer-reviewed research articles.
With this in mind, BioMed Central conducted a
short survey to assess the viability of offering paid-for
professionally written lay editor summaries on journals
and registration services. A SurveyMonkey survey was
conducted in November 2012 (Additional file 1). Emails
were sent to approximately 200 recent researchers who
had used the ISRCTN registration service in Current Con-
trolled Trials [5] and 370 BioMed Central journal editorial
board members. There were almost 50 replies with the
following findings:
 Summaries are needed at ethics approval stage in
75% of cases.
 Of the researchers surveyed, 79% do not involve lay
people [enough] and may not even see why they
should because lay summaries are ‘not difficult to
write’.
 Of the respondents, 79% either would not pay or did
not know whether they would consider paying.
Current Controlled Trials aim to continue increasing
the publication of lay summaries when their quality
meets current standards. Current Controlled Trials will also
follow changes in guidance as a result of implementations
of the INVOLVE recommendations and will continue to
discuss approaches for improving the volume and quality
of lay summaries with relevant organisations, such as the
other partners behind the UK Clinical Trials Gateway.
Discussion
The authors welcome any comments, especially ideas on
improving the transparency and accessibility for scientists
and the public.
Conclusions
All recent initiatives demonstrate that there are still a
number of challenges in making current research both
accessible and understandable by prospective participants.
It is necessary to improve ‘signposting’, to direct the public
to the information. Plain English summaries are seen as a
good idea but very few people are willing to pay for
improved content. Through extra guidance and funding,
easier access and improved quality can be attained but this
will take some time.
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